PATENT
Docket No.: **19226/931 (R-5495)**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Hangauer et al.	Examiner: T. Prasthofer
Serial No.	:	09/482,585	Art Unit: 1627
Filed	:	January 13, 2000	
For	:	A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS	

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231
Box: Non-Fee Amendment

Dear Sir:

In response to the January 30, 2001, office action, please amend the above-identified patent application as follows:

In the Specification:

Please substitute the paragraph at page 6, lines 12-13 with the following new paragraph:

A1 Figure 5 demonstrates the binding interactions of src substrate Ac-Ile-Tyr-Gly-Glu-Phe-NH_2 (SEQ. ID. No. 1) in model src active site.

Please substitute ~~the~~ paragraph at page 13, line 31 to page 14, line 5 with the following new paragraph:

A2 The standard pentapeptide sequence chosen for the majority of PKA inhibitors in Table 1 was derived from the pseudosubstrate sequence of the peptide inhibitor which was bound to PKA, when the crystal structure illustrated in Figure 1 was solved. The standard pentapeptide sequence used for src in Table 2, Ac-Ile-Xaa-Gly-Glu-Phe-NH_2 (SEQ. ID. No. 2), was described in Nair, Kim et al., 1995. Some of the chemistry used to prepare the PKA